Comparative Pharmacology
Head-to-head clinical analysis: APOGEN versus SYMADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APOGEN versus SYMADINE.
APOGEN vs SYMADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apocynin is a prodrug that is activated by peroxidases to form dimers that inhibit NADPH oxidase (NOX) enzyme complexes, reducing superoxide production. It also exhibits antioxidant and anti-inflammatory properties.
SYMADINE (amantadine) is a tricyclic amine that inhibits influenza A virus replication by blocking the viral M2 ion channel, which prevents uncoating of viral RNA. It also increases dopamine release and inhibits dopamine reuptake in the CNS, providing antiparkinsonian effects.
10 mg orally once daily, with or without food.
100 mg orally every 12 hours; immediate-release formulation.
None Documented
None Documented
Terminal half-life 3.5 hours; dose adjustment required in renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 24 hours in patients with normal renal function. In patients with renal impairment (CrCl <50 mL/min), the half-life is significantly prolonged, requiring dose adjustment. The long half-life allows for once-daily dosing.
Renal: 90% unchanged; fecal: 10% as metabolites.
Renal elimination of unchanged drug accounts for approximately 90% of the administered dose. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiviral
Antiviral and Antiparkinsonian